Neurofibromatosis type 1 (NF1) patients are predisposed to neurofibromas but the driver(s) that contribute to neurofibroma formation are not fully understood. By cross comparison of microarray gene lists on human neurofibroma-initiating cells and developed neurofibroma Schwann cells (SCs) we identified RUNX1 overexpression in human neurofibroma initiation cells, suggesting RUNX1 might relate to neurofibroma formation. Immunostaining confirmed RUNX1 protein overexpression in human plexiform neurofibromas. Runx1 overexpression was confirmed in mouse Schwann cell progenitors (SCPs) and mouse neurofibromas at the messenger RNA and protein levels. Genetic inhibition of Runx1 expression by small hairpin RNA or pharmacological inhibition of Runx1 function by a Runx1/Cbfβ interaction inhibitor, Ro5-3335, decreased mouse neurofibroma sphere number in vitro. Targeted genetic deletion of Runx1 in SCs and SCPs delayed mouse neurofibroma formation in vivo. Mechanistically, loss of Nf1 increased embryonic day 12.5 Runx1 + /Blbp + progenitors that enable tumor formation. These results suggest that Runx1 has an important role in Nf1 neurofibroma initiation, and inhibition of RUNX1 function might provide a novel potential therapeutic treatment strategy for neurofibroma patients.
INTRODUCTION
Neurofibromatosis type 1 (NF1) is a tumor-suppressor gene that encodes neurofibromin, a Ras-GTPase-activating protein.
1,2 NF1 patients are predisposed to neurofibromas, benign Schwann cell tumors. 3, 4 The molecular mechanisms of tumorigenesis and the molecules that drive neurofibroma formation are incompletely understood. Schwann cells (SCs) are believed to be the primary pathogenic cells in neurofibromas. 5 Ablation of Nf1 using Nf1 homozygous (Nf1 − / − ) embryonic stem cells or ablation of Nf1 in the Schwann cell lineage using Krox20Cre, DhhCre or PLPCre in mice lead to the development of plexiform neurofibromas. [6] [7] [8] [9] Dermal neurofibromas can develop from skin-derived progenitors through loss of Nf1. 10, 11 Proliferation of mature non-myelinating SCs is a feature of neurofibroma formation. 12 Therefore, Schwann cell progenitors (SCPs) and/or non-myelinating SCs may be cells of origin in neurofibromas.
Runt-related transcription factor-1 (Runx1 or AML1) is a transcription factor that is important for hematopoiesis, angiogenesis, maturation of megakaryocytes and differentiation of T and B cells. 13, 14 Runx1 is important for neuronal development and glial cell differentiation. [15] [16] [17] Runx1 gene is expressed in proliferating Mash1 + or NeuroD + olfactory receptor neuron progenitors on the basal side of the olfactory epithelium. 18, 19 Exogenous Runx1 expression in cultured olfactory neural progenitors causes an expansion of the mitotic cell population. 18 Runx1 has shown paradoxical effects in cancer, in which it can function either as a tumor-suppressor gene or dominant oncogene according to context. Runx1 has been implicated as a tumor suppressor in a variety of solid neoplastic diseases such as breast cancer and gastric cancer. 20 Recent evidence shows that Runx1 also acts as an oncogene in skin cancer, endometrial cancer and epithelial cancer. [21] [22] [23] Here we showed that Runx1 functions as an oncogene in neurofibromas. Specifically, the loss of Nf1 induces Runx1 overexpression in mouse neurofibromas. Genetic inhibition of Runx1 by shRNA or pharmacological inhibition of Runx1 function by a Runx1/Cbfβ interaction inhibitor, Ro5-3335, decreased mouse neurofibroma sphere number in vitro. Targeted genetic deletion of Runx1 in mouse SCs and SCPs delayed neurofibroma formation owing to decreased cell proliferation and increased cell apoptosis. Mechanistically, loss of Nf1 increased embryonic day 12.5 Runx1 + /Blbp + progenitors, which contribute to neurofibroma formation. Figure 1) . We hypothesized that genes expressed exclusively in the neurofibroma-initiating cells, but not in the differentiated neurofibromas, might contribute to tumor initiation. By cross comparing this tumor-initiating cell gene list with the previously published differentiated neurofibroma Schwann cell microarray gene list 25 and eliminating shared genes, we obtained RUNX1 as a top differentially expressed gene that was overexpressed only in the human neurofibroma-initiating cell microarray gene list (7.6-fold) (Figure 1a) .
RESULTS

Cross comparison of microarray gene lists reveals
We labeled human plexiform neurofibroma sections with an anti-RUNX1 antibody. Staining was detected in all human plexiform neurofibromas (n = 26). Three to sixty percent of human neurofibroma cells expressed RUNX1 (Figures 1b and c) .
Runx1 is overexpressed in mouse SCPs and mouse neurofibromas We used neurofibroma sphere culture, a system to determine the proliferation of SCPs, to characterize Runx1 gene expression in embryonic day 12.5 (E12.5) wild-type (WT) spheres, E12.5 Nf1 −/− mouse dorsal root ganglia (DRG) spheres, and mouse neurofibroma spheres by quantitative reverse transcription PCR (qRT-PCR). The overexpression of Runx1 was detected in all progenitors when normalized to WT SCs, but was much higher in E12.5 Nf1 −/− mouse DRG spheres and mouse neurofibroma spheres compared with WT spheres (Figure 1d ). There was a significant difference in Runx1 expression between Nf1 −/− and WT spheres (P o 0.001) or neurofibroma spheres vs WT (P o 0.001). QRT-PCR showed that Cbf-β messenger RNA (mRNA) relative expressions were within twofold range in three different neurofibromas when we normalized to age-matched WT mouse sciatic nerve mRNA expressions, and there was no significant difference in mRNA relative expression levels between these two groups (P = 0.15, not shown). Runx1 protein expression was detected by western blot and by immunofluorescence in mouse neurofibromas but rarely in WT mouse sciatic nerves (Figures 1e and f) . We performed Runx1 and Ki67 double-labeling on mouse neurofibromas to further characterize these Runx1-expressing cells. We detected Runx1/Ki67 double-positive cells (25.5% of all Runx1-positive cells or 5.9% of total cells) within these tumors (Figure 1g ), suggesting some of the Runx1-expressing cells in neurofibromas were mitotic.
Pharmacological and genetic inhibition of Runx1 decreases mouse neurofibroma sphere number in vitro To determine whether Runx1 relates to SCP number, we treated secondary Nf1 ;DhhCre mouse neurofibroma spheres detected by qRT-PCR. E12.5 WT DRG, E12.5 Nf1 −/− DRG or mouse neurofibromas from the Nf1 fl/fl ;DhhCre mouse was enzymatically dissociated and cells were cultured on low binding plates in a serum-free medium to generate SCPs as described. 24 Medium was added every 3 days. We extracted mRNA from wild-type Schwann cells (WT SCs), E12.5 WT, E12.5 Nf1 −/− and mouse neurofibroma spheres using the RNeasy mini kit (Qiagen, Valencia, CA, USA). We reverse transcribed mRNA using the Superscript System (ABI, Grand Island, NY, USA). We amplified Tubulin as a control for each sample. We carried out quantitative real-time PCR experiments in the presence of SYBR green using the Runx1 primers. We pre-formed replicate reactions in an ABI Prism 7500 Sequence Detection System Cycler according to manufacturer's instructions. We confirmed all PCR products on 2% agarose gels. We calculated ΔC t values relative to Tubulin expression. We calculated the fold changes in spheres normalized to WT Schwann cells using the equation 2 -ΔΔCt , where C t is the cycle number at the chosen amplification threshold as determined by PE Biosystems software, ΔC t = C t(Runx1) -C t(tubulin) , and ΔΔC t = ΔC t(sphere) -ΔC t(WT SCs). Statistics were performed by ordinary one way-ANOVA. (e) Western blots of Runx1 on Nf1 fl/fl ;DhhCre mouse neurofibromas and sciatic nerves. Western blots were performed as described 9 ;DhhCre DRG/tumor spheres (Figure 2b ), confirming that Runx1 contributes to sphere formation. In both cases we did not detect a Runx1 protein change because Ro5-3335 inhibits Runx1/Cbfβ interaction rather than the Runx1 protein (not shown). 26 We further tested the effects of Runx1 on sphere number using small hairpin RNAs. We infected mouse neurofibroma sphere cells with three shRunx1 lentiviruses. All three shRunx1 clones inhibited mouse neurofibroma progenitor cell number as evidenced by sphere numbers compared with nontarget control (Figure 2c ). Western blots showed the three clones knocked down 470% of Runx1 proteins compared with nontarget control (Figure 2d ).
Targeted genetic deletion of Runx1 in SCs and SCPs delays mouse neurofibroma formation in vivo
To test if Runx1 contributes to neurofibroma initiation, we targeted genetically deleted Runx1 in SCs and SCPs using a specific SCP/Schwann cell driver, Desert hedgehog (Dhh). 27 The Runx1 knockout mouse dies at E11-E12, requiring use of a conditional knock out of Runx1. We obtained the Runx1 ;DhhCre mouse neurofibroma spheres with shRunx1 and non-target control (Sigma, St Louis, MO, USA). We incubated lentiviral particles with neurofibroma spheres for 4 days and counted spheres. (d) Western blot confirmed Runx1 knockdown. **Po0.01, ***P o0.001, ns = no significant difference. Rx1 = Runx1. All statistical analyses were performed by unpaired, two-tailed student t-test.
We show that targeted genetic deletion of Runx1 in mouse SCs and SCPs delayed neurofibroma growth significantly at 4 months in the genetically engineered Nf1 ;DhhCre mouse. It is possible that phenotypes observed on conditional inactivation of Runx1 were attenuated by compensation of other Runx family members including Runx2 and/or Runx3, because all three Runx proteins bind to the same consensus sequence. 28 To determine the possibility, we performed qRT-PCR to check the relative mRNA expression levels of Runx1, Runx2 and Runx3 in DRG/tumors of Runx1 ;DhhCre mice at 1 month and 4 months of age. We normalized the relative mRNA expression levels to age-matched WT mouse sciatic nerve gene mRNA expressions. Runx1 relative mRNA expressions were ;DhhCre (n = 3) mice at 1 month and 4 months of age and age-matched wild-type mouse sciatic nerves. Relative mRNA expression levels were normalized to wild-type mouse sciatic nerves gene expressions. **P o0.01, *Po 0.05. maintained at low levels. Runx2 relative mRNA expression levels were within two-fold change. Runx3 relative mRNA expression increased significantly at 4 months (P o0.05, Figure 3f ), suggesting that Runx3 compensates for the conditional loss of Runx1 and possibly contributes to the delayed neurofibroma formation.
Loss of Nf1 leads to increase in Runx1 + /Blbp + progenitors in E12.5 DRGs Runx1 expression in mouse embryos has been reported. 17 We have shown that neurofibromas develop at E12.5 in the
Nf1
fl/fl ;DhhCre mice. 9 To determine the potential underlying mechanism of Runx1 in contributing to neurofibroma formation, we performed immunofluorescence staining of Runx1 on E12.5 WT and E12.5 Nf1 −/− mouse DRG containing SCPs, prior to embryonic death caused by loss of Nf1. We detected increased numbers of Runx1 + /Blbp + progenitors in Nf1 −/− mouse DRGs (n = 5) compared with WT controls (n = 3, P o 0.001) directly after removal from mice (Figures 4a and b) , supporting the increased Runx1 expression in SCPs on loss of Nf1. Similar results were obtained by using a different SCP marker P0 (Supplementary  Figure 2) . It has been shown that the E12.5 spheres express neural crest markers TWIST, Nestin, P75, Wint5a and Sox9 by qRT-PCR. 24 To further determine whether there are poorly differentiated Runx1-expressing SCPs on loss of Nf1, we double labeled E12.5 Nf1 −/− and WT DRGs using a neural crest marker, Nestin, with Runx1. There were increased numbers of Runx1 + /Nestin + neural crest progenitors in Nf1 −/− mouse DRGs (n = 3) compared with WT controls (n = 3, P o0.001) (Figures 4c and d (Figure 2b ). This suggests that the Runx3 compensation process might start before 2 months, but we could not determine when this process started. We could not eliminate the possibility that neurofibromas will form in the ; Dhhre tumors. We cannot exclude the possibility that other genes might also be involved in neurofibroma formation.
We showed that Runx1 mRNA expression was significantly higher in mouse E12. 30 It has also been reported that Runx1 is expressed in hair follicle, oral epithelium and intestine. Runx1 is required for the development of malignant skin squamous cell carcinoma and papilloma (benign squamous, progenitors of squamous cell carcinoma) that originate from Runx1-expressing tumor initiation cells in the hair follicle stem cells. 21 Consistent with these reports, the increased Runx1 + /Blbp + progenitors might contribute to neurofibroma formation. Targeting transcription factors, which have traditionally been considered untargetable, is becoming a realistic option with increased understanding of transcription factor biology and technological advances. We showed that the Runx1/Cbfβ interaction inhibitor Ro5-3335 decreased mouse neurofibroma sphere number significantly in vitro. The Runx1 protein binds to a consensus sequence with Cbfβ. The protein Cbfβ lacks a DNAbinding domain, but when bound to Runx1, it increases the DNAbinding affinity of the Runt domain several folds, substantially enhancing Runx1 transcriptional activity. 28 Ro5-3335 exerts its inhibitory effect on sphere formation by disruption of Runx1/Cbfβ interaction. Ro5-3335 and its analog, Ro24-7429, were initially developed as anti-HIV drugs to inhibit Tat-mediated transactivation. Ro24-7429 entered phase II clinical trial, and the drug was tolerated well by patients. It is possible that both Ro5-3335 and Ro24-7429 might show efficacy in NF1 by inhibiting Runx1/Cbfβ interaction rather than Tat. In vivo Ro5-3335 preclinical therapeutic trial using the neurofibroma mouse model will provide more information on this compound.
In summary, loss of Nf1 leads to an increase in Runx1 + /Blbp + progenitors, which enable tumor initiation. The in vitro efficacy of Ro5-3335 in reducing mouse neurofibroma sphere number suggests inhibiting Runx/Cbf-β interaction might provide a novel therapeutic target for neurofibroma treatment.
